Trading volume for Jaguar Animal Cmn was 11,917K by the end of trading on Tuesday. Overall, volume was up 360.57% over the stocks normal daily volume.
Traders are more bullish on Jaguar Animal Cmn lately if you watch the fall in short interest. The company saw a fall in short interest from September 29, 2017 to October 13, 2017 of -9.72%. Short interest decreased 216,402 over that period. The days to cover decreased to 1.0 and the short interest percentage is 0.03% as of October 13.
The following firms have recently changed their position in JAGX. Invesco Ltd. augmented its ownership by buying 1,080,000 shares an increase of 54.7% in the quarter. Invesco Ltd. owns 3,054,360 shares valued at $1,618,000. The total value of its holdings decreased 18.0%. As of quarter end Blackrock Inc. had acquired 10,160 shares growing its position 16.9%. The value of the total investment in Jaguar Animal Cmn went from $60,000 to $37,000 a change of $23,000 quarter to quarter.
Kcg Holdings, Inc. expanded its position by buying 142,063 shares an increase of 425.6% from 03/31/2017 to 06/30/2017. Kcg Holdings, Inc. now holds 175,444 shares worth $93,000. The value of the position overall is up by 181.8%. Ubs Group Ag added to its stake by buying 12,602 shares an increase of 160.0% as of 06/30/2017. Ubs Group Ag controls 20,477 shares with a value of $11,000. The total value of its holdings increased 37.5%.
In the market the company is trading down since yesterday’s close of 0.205. Jaguar Animal Cmn’s P/E ratio is N/A and the market cap is 13.01M. In the latest earnings report the EPS was $-1.04 with 67.70M shares currently outstanding.
Jaguar Animal Health, Inc., launched on June 6, 2013, is an animal health company. The Company is focused on developing and commercializing gastrointestinal products for companion and production animals, foals, and horses. Canalevia is its prescription drug product candidate, intended for treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree. The Company is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products to address needs in animal health. As of December 31, 2016, the Business’s pipeline includes prescription drug product candidates for nine indications across multiple species, and non-prescription products targeting seven species. The Business’s product candidates include Canalevia, Species-specific formulations of crofelemer, Equilevia, Virend (topical), Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm..